John Glaspy

13PUBLICATIONS
64CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersCardiovascular medicine and haematology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 05, 2026
Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer.

|Nov 27, 2024
Racial/Ethnic Disparities in Oncology Clinical Trial Participation: Investigator Attitudes, Needs, and Motivation to Improve.

Natalie P Bransky, Anne M Walling, Alexandra M Klomhaus

|Oct 10, 2024
Creating a Learning Health System in a Cancer Center: Generalizability of an Electronic Health Record Phenotype for Advanced Solid Cancer.

Anne M Walling, Karl A Lorenz, Anita Yuan

|Jun 17, 2024
Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.

Moshe Mittelman, David H Henry, John A Glaspy

|Oct 03, 2023
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.

Neil A O'Brien, Martina S J McDermott, Jun Zhang

|Aug 25, 2023
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.

Vina P Nguyen, Katie M Campbell, Theodore S Nowicki

Pageof 3

Frequent Collaborators

4 joint publications

Dennis J Slamon

4 joint publications

Neil O'Brien

3 joint publications

Jun Zhang

3 joint publications

Leonard Presta